Postmenopausal Hormone Therapy—Local and Systemic: A Pharmacologic Perspective. (3rd December 2020)

• Record Type: Journal Article
• Authors: Smith, Taryn; Sahni, Sabrina; Thacker, Holly L.
• Other Names: Kim Myong‐Jin guestEditor.; Jarugula Venkateswar guestEditor.
• Is Part Of: Journal of clinical pharmacology. Volume 60(2020)Supplement 2
• Page Start: S74
• Page End: S85
• Publication Date: 2020-12-03
• Subjects: menopause -- hormone therapy -- estrogen -- vaginal atrophy -- dehydroepiandrosterone (DHEA) -- bazedoxifene; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.1740
• Languages: English
• ISSNs: 0091-2700

Abstract

Abstract: Every woman, if she lives long enough, will transition into menopause, and as the US population ages, women will be spending more time in a postmenopausal state than before. For postmenopausal women, the decision to initiate menopausal hormone therapy should be individualized. A thorough evaluation of the patient's cardiovascular, venous thromboembolic, cancer, and fracture risk should be considered along with the woman's quality of life. Hormone therapy exerts its therapeutic effects on vasomotor symptoms, the skeleton, and the genitourinary system independent of age since menopause and these benefits are lost once hormone therapy is stopped. Here we review the pharmacologic properties dose, formulation, mode of administration, timing of initiation, and duration of hormonal therapies in regard to optimizing benefit and minimizing risk to the patient. This discussion will focus on the effects of common hormonal therapies including estrogen (local and systemic), progesterone, estrogen receptor agonist/antagonist, and local dehydroepiandrosterone and include a brief review of compounded bioidentical hormone therapy.